Online inquiry

IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5931MR)

This product GTTS-WQ5931MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5931MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9601MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8077MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ9895MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ13107MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1703MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ8284MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ14311MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ405MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW